Olivia Vizier

Sio Gene Therapies is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric disorders and adult Parkinson’s disease.

Ikena Oncology changed its name in late 2019 after a three-month deliberation process; the company previously went by Kyn Therapeutics. 

Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.

OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials

Scynexis announced it will commercially launch its Brexafemme (ibrexafungerp) therapy in the 3rd quarter of 2021 at a media event today. The company plans a full marketing rollout for its launch in the coming months.

OncoSec’s DNA-delivery system is designed to prompt the body to make more of its own IL-12. “The DNA essentially co-opts the cell’s function to cause it to make IL-12,” explained Daniel O’Connor, former CEO of OncoSec, in an interview.

A so-called multivalent vaccine might protect against all Covid-19 mutations and any future pathogen from the betacoronavirus family

Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.

Following a collaboration agreement in November 2020, Augmenta Bioworks and TFF Pharmaceuticals have selected AUG-3387 as their lead candidate in COVID-19.

The clinical-stage biopharma unveiled the $74 million series B financing Wednesday, brought in from new investors Slate Path Capital, Palkon Capital, ArrowMark Partners and 683 Capital on top of existing backers like Sporos Bioventures.

Arrowhead Pharmaceuticals has added to its collection of RNA collaborations with a $40 million upfront deal with Horizon Therapeutics.

You might expect to find Dr. Robert Hariri strolling through the headquarters of Celularity, the biotechnology company he founded, outfitted in PPE and sterile paper slippers. But when we caught up with this 62-year-old, physically fit aviator, he was in his light-filled office in the 150,000-square-foot Florham Park, New Jersey facility, wearing a black shirt, black pants, and black boots.

The furthest along is a vaccine candidate co-developed by Pfizer, the U.S.-based pharmaceutical giant, and Valneva SE, a French biotech company. In March, the companies kicked off a Phase 2 trial in 600 people ages 5-65. The vaccine, which would be given in two to three doses, is very similar to LYMErix, but it targets six strains of Lyme

At Fore Biotherapeutics, we are leveraging our functional genomics platform, Foresight, to match populations of patients with rare cancer mutations to targeted therapies that have a high probability of making a difference. Our mission is to provide patients with unaddressed cancer mutations with rapid access to the right medicines.

The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.

Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective…

Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to enhance cellular energy production.

Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.

Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French vaccine specialist.

The Houston-based preclinical biotech has raised a $15.5 million series A round led by Sporos Bioventures. The funding will go toward bringing Stellanova’s lead antibody into the clinic, building out a discovery platform and growing the team, including leadership hires later this year.

The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class of antifungal drugs in more than 20 years and propels Scynexis into the commercial realm with a potential blockbuster in tow.

But this orphan disease is one of the main reasons the team at Calliditas Therapeutics goes to work every day.

At Fountain, specifically, recent advances in AI have enabled us to spearhead a new unbiased approach to drug discovery and development.  We are using this platform to discover, refine, and advance a pipeline of disease-modifying therapies for age-related diseases, addressing both novel compounds and targets.